Journal of Proteomics & Bioinformatics

Journal of Proteomics & Bioinformatics
Open Access

ISSN: 0974-276X

+44 1223 790975

Research Article - (2017) Volume 10, Issue 7

Biopharmaceutical Potential of ACE-Inhibitory Peptides

Praveen P Balgir and Maleeka Sharma*
Department of Biotechnology, Punjabi University, Patiala, India
*Corresponding Author: Maleeka Sharma, Research Scholar, Department of Biotechnology, Punjabi University, Patiala Punjabi University, Patiala, India, Tel: +91-9872886277

Abstract

Bioactive peptides are defined as peptides with hormone or drug like activity that bind to specific receptors leading to induction of physiological responses with a positive impact on body functions and health. Though pharmaceuticals are available, the responses to these drugs show variability and outright toxicity in some patients. Peptides of food origin have been reported to play an important role in the prevention and treatment of hypertension therefore researchers are extensively exploring food based strategies to produce functional food products with antihypertensive properties. These peptides act by intervening in different biochemical pathways that control blood pressure, fluid and electrolyte balance. Some targeted pathways are the renin-angiotensin system, kinin-kallikrein system, sympathetic nervous system, ion regulation system, sodium-transport system and the endothelin-converting enzyme system. These peptides are more reactive than their native proteins and have been produced by fermentation and enzymatic hydrolysis of food sources. Recombinant DNA technology has opened more avenues of production of antihypertensive peptides. In the present work antihypertensive Angiotensin-Converting-Enzyme (ACE) inhibitor peptides (2-5 in length and from food source) were selected from BIOPEP database and validated in silico for anti-hypertensive activity using web-based software Molsoft and Molinspiration. An overall drug-likeness score for the selected peptides was calculated using Molsoft. The more positive the value of drug-likeness scores the more active the peptide is. The molecular properties like hydrophobicity, electron distribution, hydrogen bonding characteristics and molecular size of active peptides were predicted using Molinspiration. In comparison with others only eight peptides WP, PLW, YPR, LPP, FP, LW, YW, RW showed positive drug-likeness score and bioactivity score (not violating Lipinski’s rule).

Keywords: Hypertension; ACE: Angiotensin-converting enzyme; In silico; Bioactive peptides; Drug likeness score; Lipinski’s rule

Introduction

Bioactive peptides

Proteins play the major role in body functioning and are a good source of biologically active (bioactive peptides) as these peptides are specific protein fragments. According to Fitzgerald and Murray [1], bioactive peptides are defined as peptides with hormone or drug like activity that bind to specific receptors leading to induction of physiological responses [2]. The bioactive peptides as drugs have advantages such as small size, low cost and low price, oral availability, membrane-penetrating ability and stability in the physiological milieu [3]. According to their functional properties, bioactive peptides may be classified as antimicrobial, antioxidative, antihypertensive, mineral binding and opioid. Similar to the antihypertensive drugs, different classes of anti-hypertensive peptides are Angiotensin Converting Enzyme (ACE) inhibitory peptides, Renin Inhibitory peptides, Calcium channel blocking peptides, vaso-relaxative peptides, Endothelin-1 and Endothelin Converting Enzyme (ECE) inhibitory peptides [4]. The main group of the antihypertensive peptides corresponds to the inhibitors of ACE as playing an important role in the regulation of blood pressure as well as fluid and salt balance in mammals (Figure 1).

proteomics-bioinformatics-dual-functionality

Figure 1: Pathophysiology of hypertension: As a result of its dual functionality ACE is a prominent target for developing anti-hypertensive therapeutics.

ACE: Structural analysis and ACE-inhibitor pharmacokinetics

ACE is a zinc- dependent dipeptide carboxypeptidase. The resolution of the 3D structure of somatic form of ACE contains two metalloproteinase domains (N- and C-terminal domains). Each of these domains has Zn binding motif. In spite of the structural and protease activity similarity of both the domains, the C-Domain has crucial role in blood pressure regulation and is strongly activated by chloride ion (http://www.proteopedia.org/wiki/index.php/ACE). Important structural features of ACE are given in Table 1.

Annotations Details References
Domain Assignment: ACE: 575 residues SCOP DATABASE
Secondary Structure: 61% helical (31 helices; 364 residues)
3% beta sheet (7 strands; 19 residues)
DSSP databank
Structural Feature: BINDING SITE FOR RESIDUE LPR A 702
BINDING SITE FOR RESIDUE CL A 703
BINDING SITE FOR RESIDUE CL A 704
BINDING SITE FOR RESIDUE ZN A 701
BINDING SITE FOR RESIDUE GLY A2000
Site Record
Structural Feature: L-cystine (cross-link)
A protein modification that effectively cross-links two L-cysteine residues to form L-cystine.
Protein Modification DATABASE: PSI-MOD RESID Database

Table 1: Features of Angiotensin-converting enzyme.

Further, Molecular docking studies by He et al. [5] confirm that the ACE activity is through binding of peptide to enzyme active site, leading to formation of extensive hydrogen bonds. Lisinopril is a competitive inhibitor, since it has a similar structure to angiotensin I and binds to the active site of ACE (Figure 2). Molecular docking of peptides TF, LY, RALP to the active site of ACE demonstrates that these peptides bind to the hydrophobic pocket, via hydrophobic interactions with Ala354, Glu384, Tyr523, Gln281, Tyr520, Lys511, His513 and His353 residues. Peptides RALP and LY had higher ACE-Inhibition than TF because of the 4 Hydrogen bonds with the enzyme’s active site residues (Table 2).

proteomics-bioinformatics-chloride-anions

Figure 2: ACE in complex with inhibitor Lisinopril, zinc cation shown in grey, chloride anions in yellow (PDB: 1O86).

S. No. ACE residues in H-bonds Number of H-bonds
TF LY RALP LISINOPRIL
1. Glu162       1
2. Gln281   1 2 2
3. Ala354 1 1   2
4. Glu384 1 2   1
5. Asp415     1  
6. Lys511       1
7. Tyr520     1 1
8. Tyr523       1
Total 2 4 4 9

Table 2: Hydrogen bonds observed between ACE (PDB: 1O86) and the docked peptides [5].

Different sources of anti-hypertensive peptides

During the last two decades it has been found that milk proteins (human caseins, bovine and whey proteins) are a source of biologically active peptides [6]. Recent identification and characterization of bioactive peptides (in the size range of 2-20 amino acids and molecular masses of less than 6000 Da) have been obtained from cereal grains, particularly wheat, oat, barley, rice, rye, oat, millet, sorghum, corn and mushroom, algae protein waste etc. has been an emerging area [7].

Production of anti-hypertensive peptides

Biological active peptides have been produced from precursor milk proteins in the following ways:

a) Enzymatic hydrolysis.

b) Fermentation of milk with proteolytic starter cultures.

c) Genetic recombination in bacteria.

In many studies, combination of (a) and (b) or (a) and (c), has proven effective in generation of short functional peptides [8,9].

ACE-inhibitory peptides: In-silico approach

Recent trends in bio-active peptides includes designing of novel peptide sequences with potential applications in the prevention and mitigation of ill health, which has tremendous significance to the scientific community, pharmaceutical corporations and consumers. As bioactive peptides play important roles in physiological functions as signalling molecules. The fast development of bioinformatics, have led to rapid accumulation of large amount of peptide data organized in numerous biological databases such as ACEpep, AHTP, BIOPEP, EROP etc. [10]. Further, the bioinformatic tools can be used to analyze the potency of different anti-hypertensive peptides. The objective of this research work was to compare different peptides which are isolated from different food sources on the basis of physiological interpretation by Molsoft and Molinspiration software.

Materials and Methods

A total of 90 peptides (2-5 amino acids in size and from food source) were selected from BIOPEP database and analysed using Molsoft and Molinspiration.

BIOPEP database

BIOPEP (www.uwm.edu.pl/biochemia) was developed in the Chair of Food Biochemistry of Warmia and Mazury University in Olsztyn (Poland). The database provides comprehensive information on 2123 peptides representing 48 types of bioactivities, their EC50 values and source of origin. BIOPEP thus provides the useful techniques to obtain the information and classification of bioactive peptides in a quick and simple way.

Drug-likeness score using Molsoft

MolSoft provides services and software tools which leads to cheminformatics, modelling, discovery, bioinformatics, and forms with pharmaceutical companies and bioinformatics. It was founded by Ruben Abagyan in 1994. It provides tools and software’s for rational drug designing, structure prediction, bioinformatics, molecular visualization and animation, proteomics (http://molsoft.com/mprop/).

Features of MolSoft: It helps in validating and building structural models for protein targets. It gives access to identify biological ligand binding sites or new sites for allosteric regulation of interest protein. It provides molecule visualizing and data sharing. It also helps in finding out amino acid positions in protein-protein interaction. It aids in designing proteins with desired properties. It assists screening virtual libraries of millions of compounds by using the revolutionary MolSoft flexible docking and scoring procedure.

It helps in evaluating and ranking drug targets. It provides a feature of docking flexible peptides to proteins and designing peptides that blocks protein-protein interactions. It assists in predicting properties of a compound, building its QSAR models. It also helps in conversion of 2-D structure to 3-D and its clustering of large compound libraries and its analysis.

Tools and softwares of MolSoft: It provides us various free online tools are as following:

• PDB (protein databank) which is used for determining 3-D structures of biological macromolecules. This also contains bibliographic citations, 1-D 2-D structure information, atomic coordinates as well as NMR data and crystallographic structure factors.

• 2-D to 3-D convertor allows the user in construction of ICM molecular objects from 2-D drawing and promotes optimized 3-D structures using MMFF atom type assignment and force field optimization. It can be used to convert the chemical structure and view it by using iMolveiw app for mobile users and Activelcm.

• Chemical search: This tool is used to check out similarity between the structures.

• Drug-likeness is defined as a complex balance of various molecular properties and structure features (mainly hydrophobicity, electronic distribution, hydrogen bonding characteristics and molecule size) which determine whether particular molecule is similar to the known drug. For a peptide to act as drug the score should fall within the range -2.0 to 2.0 [11,12]. MolSoft uses chemical fingerprints for the prediction of drug likeness score. It was founded in 1994. It also helps in conversion of 2-D structure to 3-D and its clustering of large compound libraries and its analysis.

• Protein-protein interaction: It is used for predicting proteinprotein interaction sites on a protein by the process known as Optimal Docking Areas (ODA). It helps in identifying optimal surface patches with lowest docking desolvation energy values as calculated by ASP (atomic salvation parameters) which are derived from octanol/water transfer experiments and adapted for protein-protein docking.

• Green chemistry prediction engine: It is chemical test engine. In this we can find out the chemical that interferes biological pathway.

Softwares that are provided by MolSoft are

• ICM-browser: It is used for desktop molecule viewer.

• Active ICM: It displays fully interactive 3-D structures.

• HTML5 molecular editor: It is a molecular editor based on Java Script that is fast and lightweight.

• XPDB: It consists of fully annotated protein structure files.

KNIME nodes: It is a comprehensive licensed user-friendly data integration, processing and exploration platform (http://www.MolSoft.com).

Calculation of properties using Molinspiration

It is created by Peter Ertl and Bruno Beinfait at Novartis. It offers a wide range of cheminformatics software tools. These softwares supports molecule manipulation and processing that includes SD files and SMILES conversion, generation of tautomers, normalization of molecules, molecule fragmentation, molecular modelling and drug designing, high quality molecule depiction. Molecular database tools also support similarity and substructure searches. All the Molinspiration tools are written in JAVA. Molinspiration is now also available on ipads, smart phones. There are 434 citations in Molinspiration till 2016 and are still in count (http://www.MolInspiration.com/).

Tools and softwares of Molinspiration

• Calculation of molecular properties and bioactivity score: We can draw structures in this tool for predicting its properties. We can also paste SMILES in the SMILE box and then it will show us the whole bioactivity and molecular properties.

• Galaxy 3-D generator: In this tool we can 3-D structures of organic macromolecules.

• Molecular database-substructure and similarity search: It allows us to find similarities of our query to other structures and it also allows finding out substructures.

Molinspiration molecular viewer: With the help of this tool one can do visualization of collection of molecules in form of SD files or SMILES. It is an automatic system that transforms the SMILES into 2-D structures with the help of depiction engine (http://wiki.bkslab.org/index.php/MolInspiration) (http://www.MolInspiration.com/).

Molinspiration Parameters

• Topological molecular surface area: TPSA is defined as the surface of polar atoms. It helps in determining drug transport, intestinal absorption, drug permeability, and drug absorption. It is sum of fragments present in bimolecules such as oxygen, nitrogen etc.

• Volume: Volume of bimolecules can be calculated by s method based upon group contributions by adjusting total fragment into real 3-D volume.

• MiLogP: Log P is used for the determination of hydrophobicity. It is the octanol-water coefficient. Drug toxicity is affected by the hydrophobicity as its interaction with receptors, drug absorption and their metabolism.

• Nrotb: It is useful in determining the flexibility of molecule by measuring the no of rotatable bonds. Amide bonds are not considered because of their high rotational barrier. Rotatable bonds can be defined as any single non-ring bond, bounded to non terminal heavy atom that is non-hydrogen.

• Lipinski rule of five: this rule states that most “drug like” molecules have molecular weight less than 500, no of hydrogen bond acceptors less than or equal to 10, Log P value less than or equal to 5, no of hydrogen bond donors less than or equal to 5. Molecules that do not follow more than one of these rules may have problem with bioavailability. The rule of five determines the permeability across the cell membrane.

• Through drug likeness and molecular properties data of molecule, the bioactivity can be checked in respect to known drugs.

Results and Discussion

Drug likeness calculation of the selected peptides was done to examine that weather the peptides are bioactive based on their drug-likeness score using Drug-Likeness and molecular property prediction tool of Molsoft. The input is 2-D structure of the peptide in SMILES format, which is converted to 3-D structure and the Drug-Likeness Score is calculated as summarized in Table 3.

S. No. Peptide Food Source Molecular Weight IC50 Value(μM) Drug Likeness Score
Sequence
1. YLLF Whey protein (Beta Lacto globulin) 554.69 172 -0.47
2. FQP Fish 390.425 0 -0.32
3. GPA Milk 243.26 405 -0.46
4. ALPHA Fish 507.59 10 -0.17
5. IWHHT Fish 692.78 5.8 -0.22
6. IKP Fish 356.47 6.9 -1.06
7. LKL Fish 372.494 188 -0.77
8. HGLF α-lactalbumin and alpha-lactoglobulin 472.53 0 -0.76
9. AVP Milk 285.34 340 -1.01
10. AVPYP Casein 545.616 80 -0.47
11. PYP Milk 375.42 220 -0.24
12. PQR Casein 399.436 401 0.2
13. PFPE Casein 488.52 1000 -0.22
14. AAP Casein 257.27 0 -0.79
15. FGK Casein 350 160 -1.21
16. GRP Fish 328.35 19.9 -0.88
17. AKK Fish 345.42 3.2 -0.79
18. RY Fish 337.3 10.5 -0.79
19. LY Fish 294.3 18 -0.47
20. GWAP Fish 429.48 3.85 0.33
21. IY Fish 294.33 2.1 -0.69
22. VF Fish 264.31 9.2 -0.78
23. MF Fish 296.37 45 -0.53
24. KW Fish 332.38 1.63 0.06
25. RFH Fish 458.5 331 -0.79
26. MY Fish 312.38 193 -0.53
27. LW Milk casein 317.3 50 0.27
28. LPP Casein 325.3 9.6 0.53
29. FAP Casein 333.37 3.8 -0.13
30. VRP Casein 370.43 2.2 -1.12
31. TAP Milk 287.3 3.5 -1
32. MYY Casein 475.53 9.6 -0.53
33. ALPP Casein 396.47 0 -0.58
34. LALPP Casein 509.63 0 -0.62
35. LVL Porcine plasma 343.45 12.3 -0.77
36. GDAP Cuttlefish muscle 358.33 22.5 -0.61
37. VW Sake and sake lees 303.34 1.4 -0.03
38. VWY Sake and sake lees 466.5 9.4 0
39. YW Sake and sake lees 367.38 10.5 0.24
40. RF Sake and sake lees 321.36 93 -0.79
41. FWN Sake and sake lees 465.49 18.3 0.37
42. IYPRY Sake and sake lees 710.8 4.1 -0.68
43. VY Sake and sake lees 280.3 7.1 -0.78
44. YGGY Sake and sake lees 458.44 3.4 -0.96
45. HY Sake 318.3 26.1 -0.62
46. FP Whey Protein 262.29 315 0.53
47. VYP Whey Protein 377.4 288 -0.44
48. GKP Whey Protein 300.34 352 -0.84
49. IPA Whey Protein 299.35 141 -0.68
50. GGY Sake and sake lees 295.27 1.3 -0.87
51. IRAQQ A-zein hydrolysate 614.68 4.2 -0.64
52. VAA A-zein 259.29 13 -1.58
53. AYFYP A-casein 659.71 1001 -0.19
54. VAP A-casein 285.32 2 -1.01
55. IPP Sour Milk 325.39 5 -0.69
56. LYPVK Fig 618.75 4.5 -0.71
57. VPP Sour Milk 311.36 9 -1.07
58. VHIPP Cereals 561.66 10 -0.38
59. VHLPP Cereals 561.66 18 -0.39
60. PLW A-casein 414.49 36 0.7
61. YPRY Sake and sake lees 597.64 17.4 -0.62
62. YPR Sake and sake lees 434.47 16.5 0.53
63. PRY Sake and sake lees 434.47 2.5 -0.43
64. PR Sake and sake lees 271.3 4.1 -0.19
65. VSP Alpha-zein 301.33 10 -0.8
66. LAA Alpha-zein 273.31 13 -1.2
67. IYPR Sake and sake lees 547.63 10 -0.68
68. LSP Cereals 315.35 1.7 -0.67
69. LQP Alpha-zein 356.4 1.9 -0.38
70. LRP Cereals 384.46 1 -0.98
71. LNP Alpha-zein 342.38 43 -0.38
72. VHLAP Cereals 535.63 4.5 -0.49
73. ILP Egg 341.45 46 -0.72
74. FK Sweet potato 293.37 265.43 -0.95
75. RW Flaxseed 360.42 0.4 0.09
SVR protein 360.41 -1.12
       
76. IVF Egg yolk 377.48 260 -0.74
77. LQP Rye malt sourdough 356.42 2 -0.38
LLP 341.45 57 -0.5
78. LSA Sesame 289.16 7.8 -1.21
IVY 393.48 14.7 -0.74
LKY 422.52 0.78 -0.78
79. DW Fish 319.32 13 0.18
80. WP Cheese 301.35 217.27 0.72
81. YPYY Milk 604.66 90.9 -0.21
82. SKVYP Casein 592.69 NOT Determined (ND) -1.01
83. FGRCVSP ND ND 6.2 -1.4
84. FCF ND 415.51 ND -0.67
85. NIFYCP ND 755.89 15 -0.29
86. LRP Cereals (Maize alpha-zein) 384.48 0.29 -0.98
87. ALEP ND 428.49 ND -0.64
88. VIKP Amaranthus globulin 455.6 ND -1.1
89. LVR Fig Sap 386.49 <20 -1.06
LYPVK 618.77 4.5 -0.71
90. IAP Wheat Gliadin 299.37 2.7 -0.71

Table 3: Drug-likeness score of ACE-inhibitory peptides using Molsoft.

Out of 90 analysed peptides 13 PQR, GWAP, KW, LW, LPP, YW, FWN, FP, PLW, YPR, RW, DW, WP were found to have a positive drug likeness score. Although as shown in Figure 3 the green color indicates non drug-like behaviour and those fall under blue color are considered as drug-like but if the drug-likeness score is (>0), then it is active, if (-2.0-0.0) then the peptide is moderately active. Hence peptides having more positive values should be considered as active drug-like. Maximum drug-likeness score was found out to be 0.72 for compound WP [13,14].

proteomics-bioinformatics-model-score

Figure 3: Graph showing peptide WP to have maximum drug-likeness model score using MolSoft.

Calculation of pharmacokinetic parameters using Molinspiration

Various parameters like log P (partition coefficient), molecular weight, number of hydrogen donor, number of hydrogen acceptor and number of violation, number of rotatable bonds, molecular polar surface area TPSA were calculated for the peptides that showed positive drug-likeness score (Table 4).

Peptide TPSA NROTB HBA HBD Log P MW Lipinski’s violations
RULE ≥60 A2 ≤10 ≤10 ≤5 ≤5 ≤500 ≤1
PQR 162.98 12 10 6 -3.84 369.42 2
GWAP 157.62 9 10 6 -2.61 421.5 1
KW 134.2 10 7 7 -2.38 324.4 1
LW 108.21 8 6 5 -0.58 309.4 0
LPP 103.94 5 7 3 -1.90 325.41 0
YW 108.21 8 6 5 -0.43 343.43 0
FWN 180.40 12 10 8 -1.11 457.53 2
FP 83.36 4 5 3 -1.49 262.31 0
PLW 123.31 10 8 5 -0.17 406.53 0
YPR 125.09 10 8 4 -1.98 388.47 0
RW 120.58 10 7 5 -1.81 322.41 0
DW 145.51 8 8 6 -2.71 311.34 1
WP 99.42 5 6 4 -1.58 293.37 0

Table 4: Molinspiration calculations for pharmacokinetic parameters important for bioavailability of peptides.

TPSA, topological polar surface area; NROTB, number of rotatable bonds; MW, molecular weight; LogP, logarithm of compound partition coefficient between n-octanol and water; HBA, number of hydrogen bond donors; HBD, number of hydrogen bond acceptors.

These parameters of above 13 peptides are also calculated on the basis of Lipinski rule of five [15] gave “the rule of five” according to which orally active drugs should have a molecular weight under 500 Daltons, a maximum number of 5 hydrogen bond donors [expressed as the sum of OH and NH groups], and a maximum number of 10 hydrogen bond acceptors [expressed as the sum of N and O atoms]. The best descriptor to differentiate poorly absorbed drugs at an early stage of the drug discovery process is TPSA i.e., total polar surface area and drugs that are completely absorbed have PSA greater than or equal to 60 A2 [16]. For the calculation of drug transport properties PSA parameter is used. It is also used for the estimation of absorbance percentage. Nrotb depicts the conformational changes of a molecule which decides binding of channels or receptors. It should be equal to or less than 10 to have good oral bioavailability. Log P (lipophilicity) should have value equal to or less than 5 to fall under the range of good intestinal permeability. Out of 13 analyzed peptides 8 peptides are not violating the rule of five.

Conclusion

Although there is availability of multiple pharmacotherapies and the known preventative effects of lifestyle modification, hypertension remains a highly prevalent disorder worldwide. Due to various disadvantages of pharmaceutical antihypertensive drugs such as high fever, cough, dizziness, chills, sweating, blurred vision, hypoglycaemia, depression etc., antihypertensive bioactive peptides are used for the treatment of hypertension. ACE Inhibitors are the first-line drug of choice and these can be derived from various food sources like milk, curd, spinach, shark meat, pork, chicken, rice hydrolysate, corn, wheat, soy proteins etc.

The In-silico analysis of food protein-derived peptides is a cost- and time-effective, method to select peptides with therapeutic potential. From the 90 analysed peptides, 13 peptides had positive drug-likeness score. These peptides were further taken for calculation of Pharmacokinetic Parameters. Eight peptides WP, PLW, YPR, LPP, FP, LW, YW, RW have logP not greater than 5, molecular weight less than 500 Daltons, No. hydrogen bond donors ≤5, No. hydrogen bond acceptor ≤ 10 and does not violate Lipinski's rule. So these programs are highly useful for predicting the various properties of peptides and the results are relatable to QSAR studies.

Acknowledgements

This work was supported by the grant from DBT-Punjabi University Patiala Interdisciplinary Life Science Programme for Advance Research and Education (DBT-IPLS PROJECT) (No. BT/PR4548/ INF/22/146/2012).

Web links

http://www.molsoft.com/mprop/

http://www.molinspiration.com/cgi-bin/properties

http://vina.scripps.edu/

http://crdd.osdd.net/raghava/ahtpdb/

http://www.uwm.edu.pl/biochemia/index.php/en/biopep

http://crdd.osdd.net/raghava/ahtpin/

References

  1. FitzGerald R, Murray BA (2006) Bioactive peptides and lactic fermentations. Int J Dairy Technol 59: 118-125.
  2. Iwaniak A, Minkiewicz P (2008) Biologically active peptides derived from proteins a review. Polish J Food Nutr Sci 58: 289-294.
  3. Sun L (2013) Peptide-based drug development. Modern Chemistry & Applications 1: e103.
  4. Trivedi MS, Shah JS, Al-Mughairy S, Hodgson NW, Simms B, et al. (2014) Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J Nutr Biochem 25: 1011-1018.
  5. He R, Aluko RE, Ju XR (2014) Evaluating molecular mechanism of hypotensive peptides interactions with renin and angiotensin converting enzyme. PLoS ONE 9: e91051.
  6. Shah H (2000) Effects of milk-derived bioactives: an overview. Br J Nutr 1: S3-S10.
  7. Cavazos A, Gonzalez de Mejia E (2013) Identification of bioactive peptides from cereal storage proteins and their potential role in prevention of chronic diseases. Comprehensive Reviews in Food Science and Food Safety 12: 364-380.
  8. Pihlanto-Leppälä A (2001) Bioactive peptides derived from bovine whey proteins: opioid and ace-inhibitory peptides. Trends Food Sci Technol 11: 347-356.
  9. Balgir PP, Kaur T, Sharma M (2016) Antihypertensive peptides derived from food sources. MOJ Food Processing & Technology 2: 00024.
  10. Sharma S, Singh R, Rana S (2011) Bioactive peptides: a review. Int J Bioautomat 15: 223-250.
  11. Chandrasekaran K, Kumar Thilak R (2016) Molecular properties prediction, docking studies and antimicrobial screening of ornidazole and its derivatives. J Chem Pharmaceut Res 8: 849-861.
  12. Samant LR, Sangar VC, Rege A, Chowdhary S, Pawar S, et al. (2015) In silico ADME and Bioactivity prediction of phytoconstituents of Moringa oleifera against Alzheimer’s disease. Indo Am J Pharmaceut Res 5: 2682-2689.
  13. Lalitha P, Sivakamasundari S (2010) Calculation of molecular lipophilicity and drug likeness for few heterocycles.Orient J Chem26: 135-141.
  14. Umarani N, Ilango K, Valentina P, Ishwarya T (2012) Molecular properties prediction, synthesis and bio-evaluation of triazines glued benzothiazole congeners. Indian J Pharmaceut Educ Res 46: 366-371.
  15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23: 3-26.
  16. Palm K, Stenberg P, Luthman K, Artursson P (1997) Polar molecular surface properties predicts the intestinal absorption of drugs in human. Pharmaceut Res 14: 568-571
Citation: Balgir PP, Sharma M (2017) Biopharmaceutical Potential of ACEInhibitory Peptides. J Proteomics Bioinform 10:171-177.

Copyright: © 2017 Balgir PP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top